Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 pMMR endometrial carcinoma 5 2025-08-22
ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I… Recruiting

2023-505758-17-00 endocrine-responsive HER2-negative early breast cancer 4 2025-08-21
A Phase 2 Study of Momelotinib in Participants with low-risk myelodysplastic syndrome Recruiting

2024-519928-24-00 Myelodysplastic Syndrome 4 2025-08-21
Antiplatelet therapy added to standard thromboprophylaxis to prevent thrombosis in pancreatic cancer patients - a randomized clinical trial … Recruiting

2023-509022-22-00 Pancreatic ductal cancer 5 2025-08-21
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortison… Recruiting

2024-519667-18-00 Pancreatic conditions requiring pancreaticoduodenectomy 6 2025-08-21
Testing ivonescimab versus FOLFOX in advanced biliary tract cancer patients Recruiting

2024-515875-36-00 Advanced biliary tract cancer (BTC) 4 2025-08-18
A First-in-human Study to Evaluate the Safety and Anticancer Effect of Several Doses of TH9619 in Patients with Advanced Cancer (ODIN). Recruiting

2024-519639-40-00 Solid tumors (including Non-Small Cell Lung Cancer (NSC 1 2025-08-18
Safety and Preliminary Clinical Efficacy of MT-302 with CapOx based regimens in metastatic esophagogastric cancer (SPaCE-MT) Recruiting

2024-520213-45-00 metastatic esophagogastric cancer 9 2025-08-15
Efficacy of Reduced Gadolinium Dose in Contrast-Enhanced Breast MRI Recruiting

2024-518549-27-00 Breast Cancer 11 2025-08-14
A Phase 1/2, open-label, multicenter, dose-escalation, and dose‑optimization study to evaluate the safety, tolerability, and activity of EIK… Recruiting

2024-520395-99-00 Advanced solid tumors 7 2025-08-12
A clinical study of ifinatamab deruxtecan to treat metastatic prostate cancer (MK 2400 01A) Recruiting

2024-516036-94-00 Metastatic castrate resistant prostate cancer - mCRPC 9 2025-08-12
A clinical study of V940 and pembrolizumab in people with melanoma (V940-012) Recruiting

2024-519605-36-00 Melanoma 4 2025-08-08
Darolutamide and bipolar androgen therapy for mCRPC patients (DaroBAT) Recruiting

2025-521051-23-00 metastatic castration-resistant prostate cancer 4 2025-08-06
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma Recruiting

2024-519499-22-00 Advanced or Metastatic Hepatocellular Carcinoma 1 2025-08-04
[68Ga]Ga-FAPI PET/CT for response evaluation during immune checkpoint inhibitor therapy in malignant melanoma Recruiting

2023-509549-11-00 Malignant melanoma 4 2025-08-03
Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer Recruiting

2022-502983-19-00 High-Grade Serous Ovarian, Fallopian Tube, or Primary P 4 2025-07-31
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esoph… Recruiting

2023-509630-19-00 Esophageal Squamous Cell Carcinoma (ESCC) 5 2025-07-31
A trial comparing the treatment of rilvegostomig with fluoropyrimidine and trastuzumab deruxtecan to the standard treatment in patients with… Recruiting

2024-512583-57-00 HER2-positive locally advanced or metastatic gastric or 5 2025-07-30
A Study of BGB-16673 Compared to Investigator’s Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab or Venetoclax Plus Rituxima… Recruiting

2024-518893-15-00 Chronic lymphotic leukemia and Small Lymphocytic lympho 5 2025-07-29
A Phase 1/2 Study of Etentamig in Combination with a CELMoD Agent for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma Recruiting

2024-512146-41-00 Multiple Myeloma 9 2025-07-29
Detection of tumour DNA in the blood of patients receiving standard therapy for hormone receptor-positive (HR+) HER2 low expression (HER2 lo… Recruiting

2024-515349-41-00 Metastatic Breast Cancer HR+, HER2- 4 2025-07-29
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia Recruiting

2024-520154-38-00 Acute Myeloid Luekemia 5 2025-07-29
Durvalumab after definitive chemoradiotherapy in limited stage small cell lung cancer Recruiting

2025-521340-37-00 small cell lung cancer 5 2025-07-24
Phase 1b/2 dose-escalation trial of OMTX705, an anti-fibroblast activation protein antibody-drug conjugate, in combination with regorafenib … Recruiting

2025-520743-33-00 Advanced/metastatic colorectal cancer 9 2025-07-23